(本文来自第一财经) 百济神州跌超8%，药明生物跌超7%，泰格医药、康龙化成跌超5%，君实生物、药明康德、诺诚健华等 跟跌。 ...

根据2026年2月25日披露数据，VITASOY INT'L（00345）、恆生科技ETF（03032）、永升服务 （01995）港股通持股占比增加值最大，分别增加0.09%、0.04%、0.01%；南方恆生科技（03033）、医 渡科技（02158）、盈富基金（02800）港股通持股占比减少值最大，分别减 少-0.14%、-0.03%、-0.02%。 2、港股通最新日占比减持榜（前20名） | 公司名称 | 占比值变动 | 最新持股比例 | | --- | --- | --- | | 南方恆生科技(03033) | -0.14% | 68.87% | | 医渡科技(02158) | -0.03% | 22.59% | | 盈富基金(02800) | -0.02% | 3.49% | | 碧桂园(02007) | -0.01% | 17.75% | | 南方恆生生科(03174) | 0.00% | 0.36% | 在最近有统计数据的5个交易日内，南方东西精选（03441）、喜相逢集团（02473）、兆易创新 （03986）港股通持股占比增加值最大，分别增加18.46%、10.04%、4.95%；山东墨龙（0 ...

| 股票名称 | H股(港元) | A股 | 溢价率↓ | 偏离值 | | --- | --- | --- | --- | --- | | 东北电气(00042) | 0.315 | 2.25 | 757.14% | -50.71% | | 京城机电股份 | 4.380 | 14.1 | 285.62% | 12.60% | | (00187) | | | | | | 中石化油服(01033) | 1.010 | 3.22 | 282.18% | -2.51% | | 弘业期货(03678) | 3.190 | 9.96 | 273.98% | 2.61% | | 南京熊猫电子股份 | 5.280 | 14.78 | 235.23% | -0.03% | | (00553) | | | | | | 凯盛新能(01108) | 4.070 | 11.11 | 227.03% | 1.59% | | 钧达股份(02865) | 35.700 | 97.15 | 225.97% | -17.30% | | 复旦张江(01349) | 3.200 | 8.62 | 222.81% | -15.46% | | 安德利果 ...

业务与技术发展 2026年初，泰格医药通过日本子公司以2348万元收购MICRON公司56.37%股权，旨在拓展医学影像评 估等海外业务。该交易可能提升全球服务能力，但需关注标的公司的亏损整合情况。公司海外布局已覆 盖33个国家，国际多中心临床试验项目达150个，未来地缘政策风险下的全球化策略值得留意。 行业政策与环境 临床CRO行业随创新药投融资回暖而复苏，经营活动现金流预计达11亿-13亿元（2025年），同比略有 提升。公司龙头地位稳固，但需观察国内集采常态化及国际监管环境（如美国《生物安全法案》）对业 务的影响。 经济观察网 泰格医药于2026年1月29日披露2025年业绩预告，预计归母净利润同比增长105%至204%， 但扣非净利润同比下降43%至61%，主要受非经常性损益（如金融资产投资收益）驱动。机构如瑞银和 高盛在研报中强调，需重点关注公司对2026年新签订单的价格复苏信号、收入及利润指引的后续披露。 高盛将H股目标价微调至66.4港元，瑞银维持目标价57.1港元，均提及"买入"评级。 业绩经营情况 泰格医药于2026年1月29日披露2025年业绩预告，预计归母净利润同比增长105%至204% ...

Group 1 - In 2025, China's foreign trade showed strong resilience, with total exports reaching a historical high, growing by 5.5% year-on-year, despite a complex external environment [1][57] - China's trade surplus exceeded $1 trillion for the first time, marking a significant increase of 19.8% year-on-year [1][57] - The net export of goods and services contributed 1.64 percentage points to GDP growth, the second-highest level since 2007, only behind 2021 [3] Group 2 - The diversification of external demand has strengthened, with emerging markets compensating for the decline in exports to the US, which fell by 19.79% year-on-year [6] - Exports to ASEAN, Africa, and the Middle East saw significant growth rates of 25.9%, 13.64%, and 9.7% respectively, contributing positively to the overall export scale [6] - The share of US exports in China's total exports decreased by 3.53 percentage points to 11.15% [6] Group 3 - The product structure of China's foreign trade is shifting towards higher value chains, with high-end products like electrical machinery, machinery, automobiles, and ships being the main export drivers [8] - Traditional light industrial products such as furniture and toys have seen a decline in export scale due to tariff friction and industrial chain relocation [8] Group 4 - The restructuring of global supply chains is creating significant opportunities for Chinese companies, with a notable increase in the number of Chinese enterprises establishing production capacities abroad, reaching 229 in 2025, nearly doubling from 2024 [18] - ASEAN, Mexico, and India are the primary destinations for Chinese production capacity outflows, with ASEAN covering a wide range of industries [18] Group 5 - The AI expansion cycle is a core focus in the Chinese capital market, with significant growth expected in AI computing hardware, supported by macro investment scales and healthy balance sheets of major tech companies [29][30] - The capital expenditure of major cloud service providers is projected to increase significantly, reflecting strong demand for AI computing [35] Group 6 - Cultural and technological value output is becoming a major trend for Chinese enterprises going abroad, with significant growth in IP exports and innovative products in sectors like gaming and new dining [39][41] - The Chinese innovative pharmaceutical sector is increasingly integrated into the global supply chain, with more products commercialized in the US and Europe [41] Group 7 - Key sectors with strong overseas expansion opportunities in 2026 include new energy (batteries, grid equipment), machinery, TMT (technology, media, telecommunications), and innovative pharmaceuticals [46] - The gaming industry is also highlighted for its potential, with significant overseas revenue growth expected [49]

Group 1 - The article highlights the top three companies with the highest AH premium rates: Northeast Electric (00042) at 785.25%, Beijing Jingcheng Machinery Electric (00187) at 291.45%, and Sinopec Oilfield Service (01033) at 284.04% [1] - The bottom three companies with the lowest AH premium rates are CATL (03750) at -16.62%, WuXi AppTec (02359) at -6.17%, and China Merchants Bank (03968) at -3.27% [1] - The article provides a detailed ranking of the top ten and bottom ten AH stocks based on their premium rates and deviation values, indicating significant disparities in market valuations between A-shares and H-shares [1][2] Group 2 - The top three companies with the highest deviation values are Beijing Jingcheng Machinery Electric (00187) at 23.16%, Dongjiang Environmental Protection (00895) at 18.78%, and Zhongzhou Securities (01375) at 16.54% [1] - Conversely, the companies with the lowest deviation values include Morning Paper (01812) at -52.60%, Junda Co., Ltd. (02865) at -34.18%, and Changfei Optical Fiber Cable (06869) at -34.18% [1][2] - The article emphasizes that the deviation value represents the difference between the current premium rate and the average premium rate over the past 30 days, providing insights into market trends [2]

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [1]. Core Views - The clinical CRO industry is experiencing a recovery, with increasing demand driven by the global rise in innovative drug financing and the expansion of clinical trial outsourcing. The company is expected to benefit from this trend, with a significant increase in new orders and market share [8]. - The company has established itself as a leader in the clinical CRO market in China, with its market share rising from 8.7% in 2019 to 12.8% in 2023. This growth is attributed to the optimization of supply and the company's strong competitive position [8]. - The company's revenue and profit forecasts indicate a recovery, with expected revenues of 71.29 billion yuan in 2025, 80.19 billion yuan in 2026, and 93.27 billion yuan in 2027, alongside a substantial increase in net profit [8]. Summary by Sections Company Overview - Founded in 2004, the company has grown to become a leading clinical CRO in China, providing comprehensive services for the biopharmaceutical industry through self-built and acquired networks [14]. - The company's ownership structure is stable, with key founders holding significant shares and a management team experienced in top-tier biopharmaceutical companies [15]. Financial Analysis - The company has experienced revenue growth from 254 million yuan in 2012 to 6.603 billion yuan in 2024, with a compound annual growth rate (CAGR) of 28.5%. However, growth has slowed in 2023 and 2024 due to market conditions [19]. - The company’s gross margin has faced pressure, but a recovery is anticipated in 2026 as low-priced orders are cleared and new orders increase [22]. Industry Outlook - The global demand for CRO services is expected to grow, with the penetration rate of outsourced pharmaceutical R&D projected to exceed 50% by 2024 and reach approximately 65% by 2033 [43]. - The number of CRO companies in China has decreased significantly due to market consolidation, enhancing the competitive landscape for leading firms like the company [52]. Business Segments - The company operates primarily in two segments: Clinical Trial Technical Services (CTS) and Clinical Trial Related Services and Laboratory Services. CTS is the cornerstone of the business, covering all phases of clinical trials [54]. - The company has a strong international presence, with operations in 33 countries and a growing number of overseas projects, reflecting its commitment to global expansion [63].

证券之星消息，2月13日，医疗健康（980016）指数报收于6089.34点，跌1.41%，成交197.5亿元，换手 率0.76%。当日该指数成份股中，上涨的有3家，片仔癀以0.96%的涨幅领涨，下跌的有47家，泰格医药 以4.9%的跌幅领跌。 资金流向方面，医疗健康（980016）指数成份股当日主力资金净流出合计10.64亿元，游资资金净流入 合计1.07亿元，散户资金净流入合计9.56亿元。成份股资金流向详情见下表： 医疗健康（980016）指数十大成份股详情如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 ...

Group 1 - The core viewpoint of the article is that Tigermed (stock code: 300347) has disclosed its 2025 performance forecast, indicating a significant decline in net profit excluding non-recurring gains, while net profit attributable to shareholders is expected to more than double due to non-recurring income [1][2]. Group 2 - For the year 2025, the company expects its net profit excluding non-recurring gains to be between 330 million to 490 million yuan, representing a year-on-year decline of 43% to 61% (compared to 855 million yuan in the previous year) [2]. - The decline in net profit excluding non-recurring gains is primarily attributed to issues with existing orders, including cancellations and payment pressures from clients, particularly from domestic biotech startups and some vaccine companies reliant on external financing [2]. - Increased costs due to the expansion of clinical operations, project management, and business development teams in response to industry demand recovery have also contributed to the decline in profitability [2]. - The average price of new orders has decreased due to intense industry competition in recent years, impacting the profit margins of projects executed in 2025; however, the company noted that the average price of new orders has stabilized [2]. - Despite the decline in net profit excluding non-recurring gains, the company anticipates a substantial increase in net profit attributable to shareholders, projected to be between 830 million to 1.23 billion yuan, reflecting a year-on-year growth of 105% to 204%, mainly driven by significant increases in non-recurring gains such as investment income and fair value changes [2].

泰格医药的订单情况有所改善，但市场更关注公司的订单转化收入效率及投资变现能力。由于短期利好 因素已反映在股价，相信其风险与回报已趋于平衡。 里昂发布研报称，下调泰格医药（300347）(03347)2027财年盈测7%，以反映长期投资收益的不确定因 素增加。该行续予泰格医药"跑赢大市"评级，当中将H股目标价由68.2港元下调至59.9港元，并将泰格 医药(300347.SZ)A股目标价由81.9元人民币降至72元人民币。 ...